港股異動丨海吉亞醫療大漲超17% 股東增持+業績增長
海吉亞醫療(6078.HK)大幅拉昇漲超17%,報15.78港元,成交額放大至3.43億港元,總市值97.5億港元。據聯交所披露信息,3月28日和3月31日,海吉亞醫療(6078.HK)獲公司創始人、控股股東、董事會主席兼首席執行官朱義文先生再度增持,合計增持61.54萬股。自公司上市以來,朱義文先生已20次在二級市場增持公司股票,從未減持過公司股票,對公司未來發展充滿信心。日前公司公佈,24年營業收入44.5億,再創歷史新高,其中手術收入同比提升21.2%;全年就診人次453萬人,同比增長23.8%。公司調整後經營活動現金淨額8.2億,EBITDA11.1億,持續穩健增長,彰顯韌性。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.